Skip to main
  1. Stocks
  2. Amgen
  3. Forecast
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 26 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 62%
Sell 8%
Strong Sell 0%

Bulls say

Amgen is supported by a broad, diversified portfolio that is delivering both scale and innovation, as 3Q 2026 sales of $10.37B and EPS of $6.45 beat expectations while the company raised FY 2026 guidance to $38.9B-$39.7B in sales and $22.90-$23.70 in non-GAAP EPS. Growth is being led by newer assets such as Imdelltra, which generated $406M and showed compelling clinical data in 1L ES-SCLC, alongside Uplizna, while the expanding biosimilar franchise added another layer of recurring momentum. The firm also appears financially resilient, with operating margin guidance of ~45%-46% and management signaling no step-down in 2027, supporting confidence in durable earnings power despite some offsets from Tepezza, Prolia, and Xgeva.

Bears say

Amgen is facing multiple fundamental headwinds that justify a negative outlook, with the text explicitly flagging downside risks from disappointing MariTide data, stronger competitor obesity drugs, faster biosimilar erosion of Prolia and Xgeva, adverse IRS litigation outcomes, and tariff developments. Confidence in its long-duration growth pipeline is also pressured by read-through risk from pelacarsen’s primary-endpoint miss, since weak Lp(a) outcome data would further undermine optimism around olpasiran’s 2028 trial. Meanwhile, the company’s legacy franchises already show erosion in key markets, and the cited revenue trajectories point to meaningful year-over-year declines in several segments, suggesting that newer launches may not offset loss of exclusivity and competitive pressure quickly enough.

Amgen (AMGN) has been analyzed by 26 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Amgen (AMGN) Analyst Forecast & Price Prediction

Get the latest Amgen (AMGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Amgen (AMGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 26 analysts, Amgen (AMGN) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $441.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $441.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Amgen (AMGN) Analyst Forecast & Price Prediction

Get the latest Amgen (AMGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Amgen (AMGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AMGN stock data and trends